Paragon 28, Inc. (FNA) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Paragon 28, Inc. (FNA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Paragon 28, Inc. (FNA)

Company Performance

Current Price

as of Oct 16, 2024

$5.83

P/E Ratio

N/A

Market Cap

$487.05M

Description

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Metrics

Overview

HQEnglewood, CO
SectorHealth Technology
IndustryMedical Specialties
TickerFNA
Price$5.83+1.57%

Trading Information

Market Cap$487.05M
Float46.52%
Average Daily Volume (1m)384,114
Average Daily Volume (3m)544,784
EPS-$0.83

Company

Revenue$235.44M
Rev Growth (1yr)19.62%
Net Income-$13.78M
Gross Margin67.43%
EBITDA Margin-10.09%
EBITDA-$6.16M

EV$632.32M
EV/Revenue2.69
P/EN/A
P/S2.06
P/B3.32

Documents

Earnings Calls

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report 2023Q4

Earnings Report (2023-11-11)

Earnings Report (2023-08-06)

Factset

Factset Business Description

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Paragon 28 Q3 (2023-11-08T12:43:33Z)

Paragon 28 reports Q3 adjusted EBITDA $1.2M vs FactSet ($1.7M) [7 est, ($4.4)-0.1M] ($10.35, 0.00) (2023-11-07T22:15:09Z)

Paragon 28 announces new $150M credit facility replacing existing $90M credit facility ($10.35, 0.00) (2023-11-07T22:14:08Z)

Paragon 28 adds second mobile medical education Lab ($9.45, 0.00) (2023-11-13T21:25:08Z)